Results of Phase I Clinical Study of Qilu Pharma’s PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
(Adnkronos) – JINAN, China, May 12, 2023 /PRNewswire/ — On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical
